Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates

Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of$ 0.23. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 21.74%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 0.21 per share when it actually produced a loss of $0.25, delivering a surprise of -19.05%.Over the last four quarters, t ...